13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ODONATE CONTESSA

    Acronym: 

    ODO-TE-B301

    ACTRN/NCT /ethics: 

    NCT03326674

    Scientific title: 

    Tesetaxel plus reduced dose of Capecitabine vs. Capecitabine in HER2 negative, HR positive, MBC (Contessa)

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Female Anticipated Start Date 2017-12-21
    Molecular Target Anticipated End Date 2023-03-01
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2017-12-21
    Anticipated End Date 2023-03-01

    Trial Summary

    A multinational, multicenter, randomised, phase 3 study of Tesetaxel plus a reduced dose of Capecitabine versus Capecitabine alone in patients with HER2 negative, hormone receptor positive, locally advanced or metastatic breast cancer previously treated with a Taxane.

    Lay Summary

    Tesetaxel plus reduced dose of Capecitabine vs. Capecitabine in HER2 negative, HR positive, MBC (Contessa)

    Sponsor / Cooperative group

    Odonate Therapeutics

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Sina Vatandoust Recruiting